EUVIMEDScopri EUVIMED
Crossref

New Schiff Base Derivative Triazines: Their Synthesis, Molecular Docking Studies, and Anticancer Activities in Human Lung Cancer Cells

Elif Şenkuytu iD, Seda Mesci iD, Deryanur Kılıç, Burak Yazgan, Tuğba Taş Özdemir, Tuba Yıldırım

Chemical Biology & Drug Design · 2026-04 · 107 (4)

DOI: 10.1111/cbdd.70278 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2026-03-30. Written by Elif Şenkuytu and 5 co-authors. Institution: Department of Chemistry, Science of Faculty, Atatürk University, Erzurum, Turkey. Major MEDLINE topics: Antineoplastic Agents, Triazines. 96 references. Funded by: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (TUBITAK), Atatürk Üniversitesi.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Lung cancer has high mortality rates among both men and women worldwide. Nevertheless, mortality rates have been reported to decline with the advancement of novel therapeutic agents and the identification of new molecular targets. Schiff bases and triazine compounds have significant biological activity. For this purpose, new Schiff base derivative triazine compounds ( TrzSchf 1–3 ) were synthesized in our study. The activities of the new compounds, characterized by spectroscopic techniques, against A549 lung cancer and MRC5 normal lung cells were identified in a series of studies. It was observed that TrzSchf 1–3 generally showed a growth‐inhibitory effect against lung cancer cells (A549) and a non‐toxic effect against normal lung cells (MRC5). Notably, TrzSchf 1 and TrzSchf 2, 3 exhibited prominent cytotoxic effects in A549 cells, with IC 50 values of 14.24 and > 50 μM, respectively. It was observed that the compound with the most potent cytotoxicity against lung cancer cells was TrzSchf 1 (Selective Index: 3.62). In A549 cells, an increase in MAPK gene expression was observed for all compounds. It was observed that the expression of Caspase‐3, CD40, CHK1, P27, P38, and P53 proapoptotic proteins increased by all compounds ( TrzSchf 1–3 ), whereas the expression of antiapoptotic proteins such as BCL‐2 and NFκB decreased by these compounds. The compounds are thought to be potential inhibitors of BCL‐2 and NFκB, which are associated with cell death. Complementary and guiding in silico studies supported the experimental findings. BCL‐2 was determined as the most favorable molecular target based on docking scores, and e‐pharmacophore modeling further revealed key interaction features and enabled SAR analysis. The drug‐likeness potential of the TrzSchf derivatives was evaluated based on Lipinski's Rule of Five parameters. Overall, both experimental and computational results suggest that TrzSchf 1–3 are promising lead candidates for further investigation in lung cancer therapy.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsTriazinesHumansMolecular Docking SimulationSchiff BasesLung NeoplasmsApoptosisA549 CellsCell Line, TumorCell Proliferation

Author keywords

Schiff basecell cyclecell deathlung cancermolecular dockingtriazine

Substances

Schiff BasesAntineoplastic AgentsTriazines

Authors and institutions

  • Department of Chemistry, Science of Faculty, Atatürk University, Erzurum, Turkey.
  • Project Coordination and Guidance Office, Rectorate, Hitit University, Çorum, Turkey.
  • Department of Medical Services and Techniques, Amasya University, Amasya, Turkey.
  • Department of Biotechnology, Institute of Science, Amasya University, Amasya, Turkey.

ORCID profiles: Elif Şenkuytu, Seda Mesci

Funding

  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (TUBITAK)
  • Atatürk Üniversitesi

Cite

APA

Şenkuytu, E., Mesci, S., Kılıç, D., Yazgan, B., Özdemir, T. T., & Yıldırım, T. (2026). New Schiff Base Derivative Triazines: Their Synthesis, Molecular Docking Studies, and Anticancer Activities in Human Lung Cancer Cells. Chemical Biology & Drug Design, 107(4). https://doi.org/10.1111/cbdd.70278

Vancouver

Şenkuytu E, Mesci S, Kılıç D, Yazgan B, Özdemir TT, Yıldırım T. New Schiff Base Derivative Triazines: Their Synthesis, Molecular Docking Studies, and Anticancer Activities in Human Lung Cancer Cells. Chemical Biology & Drug Design. 2026;107(4). doi:10.1111/cbdd.70278

BibTeX
@article{enkuytu2026,
  author = {Şenkuytu, Elif and Mesci, Seda and Kılıç, Deryanur and Yazgan, Burak and Özdemir, Tuğba Taş and Yıldırım, Tuba},
  title = {New Schiff Base Derivative Triazines: Their Synthesis, Molecular Docking Studies, and Anticancer Activities in Human Lung Cancer Cells},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {4},
  doi = {10.1111/cbdd.70278}
}
Start for free →